Iron Deficiency Anemia Clinical Trial
Official title:
Iron Deficiency, Depression, and Other Affective Disorders in Female State Fair Attendees
This study aims to examine iron deficiency symptoms and biochemical iron status based on hemoglobin, hematocrit, ferritin, and total iron binding capacity in menstruating females.
Iron deficiency affects nearly 2 billion people globally, and it is among the most common
risk factors for disability and death. In its most extreme presentation, it results in
anemia, where the RBC count of the individual is markedly low, hindering oxygen transport.
Anemia has a remarkable global presence, affecting approximately one third of the world's
population. Though there are multiple causes for anemia, the World Health Organization (WHO)
estimates that the most common cause for anemia on the planet is iron deficiency. Although
findings from the US indicate that iron deficiency is less prevalent than in many other
nations, iron deficiency is still a pervasive national public health concern. A study that
analyzed the National Health and Nutrition Examination Survey (NHANES) data from 2007-2010
indicated that US children 5 years of age and younger have an anemia incidence of 3.2
percent.
Incidence of depression varies based on diagnostic tools used and categories included, as
well as the country, gender, age, and socioeconomic status of individuals. Globally, it is
estimated that between 4 and 10 percent of people experience major depressive disorder (MDD)
while between 2.5 and 5 percent experience dysthymia, a depression that involves less severe
symptoms but has a chronic manifestation. On average, the first onset of depression is 20
years old, though this figure is highly variable. It has consistently been demonstrated that
females experience a much higher incidence of depression than males. MDD has repeatedly been
reported in females at rates 1.5 to 3 times that of males, and female dysthymia has been
reported at 2 times that of males.
The current state of the literature on the connection between mental health and iron status
is further muddled by subjective, self-reported assessments and a lack of randomized
controlled trials, but the evidence certainly suggests an association. Affective
characteristics studied in relation to iron deficiency include irritability, anger, or mood;
depression, both as postpartum depression (PPD) or depression independently; and perceived
QOL. Differences in assessment tools as well as length and dosage of iron treatment likely
play a pivotal role in discordant results. Most studies also include fatigue as a primary
outcome as it is closely tied to these affective characteristics.
The aim of this study is to further investigate iron status and iron deficiency symptoms in
menstruating females. It builds on the existing research for use of cutoff values for various
biochemical assessments of iron as well as for stages of deficiency in which symptoms are
experienced. In addition, the association between iron status, measured either biochemically
or by self-reported iron deficiency symptoms, and depression was examined.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06027801 -
Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity
|
N/A | |
Completed |
NCT02282553 -
Gastric Capsule Examination for Iron Deficiency Anaemia
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT04913649 -
Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients
|
Phase 4 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01438645 -
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
|
N/A | |
Completed |
NCT01307007 -
Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding
|
Phase 2 | |
Completed |
NCT00982007 -
Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
|
Phase 3 | |
Completed |
NCT00198848 -
Iron Supplementation Among Adolescent Girls in India
|
N/A | |
Completed |
NCT01166451 -
The Anemia Control Program: High or Low Iron Supplementation
|
N/A | |
Recruiting |
NCT03893045 -
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
|
Phase 3 | |
Recruiting |
NCT03817957 -
Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency
|
Phase 3 | |
Completed |
NCT03819530 -
Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study
|
N/A | |
Completed |
NCT03618914 -
Anemia and Inflammation
|
||
Completed |
NCT03940430 -
Lactoferrin Versus Ferrous Sulfate in Management of Iron Deficiency Anemia Among Female Medical Ain Shams Students
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03873584 -
Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
|
||
Enrolling by invitation |
NCT03897673 -
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas
|
N/A | |
Active, not recruiting |
NCT04778072 -
A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects
|
N/A | |
Completed |
NCT03237065 -
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
|
Phase 3 | |
Completed |
NCT05153278 -
IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department
|